| Date Filed | Type | Description |
| 08/14/2023 |
15-12G
| Form 15-12G - Securities registration termination [Section 12(g)]: |
| 08/07/2023 |
8-K
| Submission of Matters to a Vote of Security Holders, Other Events Interactive Data |
| 07/11/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 07/10/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E... |
| 07/06/2023 |
SC 13D/A
| SIGMA TAU FINANZIARIA SPA reports a 36.1% stake in RegeneRx Biopharmaceuticals, Inc. |
| 04/03/2023 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405: |
| 11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 08/12/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 05/16/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 03/30/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 11/17/2021 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 11/15/2021 |
10-Q
| Quarterly Report for the period ended September 30, 2021 |
| 11/15/2021 |
8-K
| Investor presentation |
| 10/19/2021 |
DEFR14A
| Form DEFR14A - Revised definitive proxy soliciting materials: |
| 10/18/2021 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 10/08/2021 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 09/07/2021 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 09/02/2021 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 08/17/2021 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
| 08/06/2021 |
10-Q
| Quarterly Report for the period ended June 30, 2021 |
| 07/22/2021 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 05/14/2021 |
10-Q
| Quarterly Report for the period ended March 31, 2021 |
| 05/14/2021 |
8-K
| Quarterly results |
| 03/19/2021 |
8-K
| Quarterly results |
| 03/02/2021 |
10-K
| Annual Report for the period ended December 31, 2020 |
| 02/08/2021 |
5
| GOLDSTEIN ALLAN L (Director) has filed a Form 5 on REGENERX BIOPHARMACEUTICALS INC |
| 11/13/2020 |
10-Q
| Quarterly Report for the period ended September 30, 2020 |
| 10/21/2020 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 10/16/2020 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 10/13/2020 |
8-K
| Quarterly results |
| 08/17/2020 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 08/17/2020 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 08/14/2020 |
10-Q
| Quarterly Report for the period ended June 30, 2020 |
| 05/15/2020 |
10-Q
| Quarterly Report for the period ended March 31, 2020 |
|